Open Nav

Aegle Therapeutics Corp.

Fund our Series A; establish partnerships/collaborations

  • Date:Wednesday, October 17
  • Time:9:00 AM - 9:15 AM
  • Room:Elizabethan D
  • Location:2nd Floor
  • Session Type:Company Presentation
  • Presentation Type:Privately Funded Company
  • Company Description/Mission Statement:Aegle Therapeutics Corp. is a first in class, Phase I/IIa-ready, biotechnology company isolating extracellular vesicles (“EVs”) secreted by allogeneic bone marrow derived mesenchymal stem cells (“BM-MSCs”) to treat severe dermatological conditions. Aegle’s platform technology is initially being developed to treat epidermolysis bullosa (“EB”), a rare pediatric skin blistering disorder, and burns (including scarring prevention). Aegle has been cleared by the FDA to enter the clinic to treat burn patients with its EV therapy. Aegle will be filing an additional IND for the treatment of dystrophic EB with its EV therapy in the fourth quarter of 2018. Aegle was founded to harness the regenerative healing power of mesenchymal stem cells without using the cells as therapy. While EVs are the paracrine wound healing mediators of cells, they are not living, and therefore may provide a safe, lower cost alternative to using cells as therapy.
  • Company
  • Company HQ City:Miami
  • Company HQ Country:United States
  • Company HQ State:Florida                        
  • CEO/Top Company Official:Shelley A. Hartman
  • Year Founded:2013
  • Main Therapeutic Focus:Dermatology
  • Lead Product in Development :EV Therapy
  • Development Phase of Primary Product:Phase I
  • Total Amount Raised to Date, In All Rounds:>$15million from grants to fund research; $0.5mm insider round
Shelley Hartman
Aegle Therapeutics Corporation